Late last Friday, the US Drug Enforcement Agency (DEA) released a proposed rule to make permanent some of the flexibilities allowed during the Public Health Emergency (PHE) for telemedicine companies whose providers prescribe controlled substances. In a recent post, our friends at Nixon Gwilt Law Group share updates on:
-
What these proposed changes are;
-
How they will impact your telemedicine business; and
-
Where (and how) stakeholders can weigh in on the DEA’s proposal in the 30-day comment period.